Track topics on Twitter Track topics that are important to you
We discover and develop pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body's blood vessels and related organs. We intend to commercialize a novel class of drugs that focus on a new treatment approach we call "HDL Therapy," which is based on our understanding of high density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway. The RLT pathway is responsible for removing excess cholesterol from arteries and other tissues and for its transport to the liver for elimination from the body. Our goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. We currently have five product candidates under development for the treatment of cardiovascular disease.
3621 S. State Street, 695 KMS Place
United States of America
Phone: (734) 332 0506
Fax: (734) 332 0516
Esperion Therapeutics announced plans to raise $150 million in a follow-on that will fund its program for the drug combinatio -More-
PLYMOUTH, Mich., Jan. 3, 2013 /PRNewswire/ -- Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced that company...
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Esperion hits goal in LDL trial, pulls forward NDA target date .A phase 2 tri...
Presentation on Wednesday, June 7, 2017 at 10:30 a.m. Eastern Time ANN ARBOR, Mich., May 31, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focuse...
Stifel Financial Corp acquired a new position in Esperion Therapeutics, Inc. during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The fi...
PLYMOUTH, Mich., Jan 4, 2013 /PRNewswire/ -- Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced t...
Esperion Therapeutics Inc. (cardiovascular disease treatments) netted $142.8mm through the public offering of 3.1mm common shares at $49. The company will use the proceeds to fund the ongoing CLEAR ca...
Esperion Therapeutics, Inc. , the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective once-daily, oral therapies for the treatment of patients ...
Esperion Therapeutics, Inc., located in Plymouth, Michigan, discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company is funded by top tier venture...
Esperion Therapeutics, Inc.Â is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for...
We discover and develop pharmaceutical products for the treatment of cardiovascular disease, which is disease of the heart and the body's blood vessels and related organs. We intend to commercialize a...
We have published hundreds of Esperion news stories on BioPortfolio along with dozens of Esperion Clinical Trials and PubMed Articles about Esperion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Esperion Companies in our database. You can also find out about relevant Esperion Drugs and Medications on this site too.
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...